

Original Article

## Evaluation of Liver Enzymes, Hematologic and Coagulation Factors in Patients with Chronic Kidney Disease

Alireza Balizadeh Karami<sup>1</sup>, Atefeh Zahedi<sup>2</sup>, Naser Kamyari<sup>3</sup>, Hoda Mojiri-Forushani<sup>4</sup>, Tina Eghdampanah Foumani<sup>1</sup>, Mohammad Mehdi Shadravan<sup>1</sup>, Khadijeh Kanani<sup>5</sup>, Esmat Radmanesh<sup>6\*</sup>

<sup>1</sup>Student Research Committee, Abadan University of Medical Sciences, Abadan, Iran

<sup>2</sup>Department of Public Health, Asadabad School of Medical Sciences, Asadabad, Iran

<sup>3</sup>Department of Public Health, School of Health, Abadan University of Medical Sciences, Abadan, Iran

<sup>4</sup>Department of Pharmacology, School of Medicine, Abadan University of Medical Sciences, Abadan, Iran

<sup>5</sup>Clinical Research Development Unit, Taleghani Educational Hospital, Abadan University of Medical Sciences, Abadan, Iran

<sup>6</sup>Department of Physiology, School of Medicine, Abadan University of Medical Sciences, Abadan, Iran

### HIGHLIGHTS

- In patients with CKD renal markers (creatinine and BUN) were higher than normal.
- In patients with CKD coagulation factors (PT, PTT, and INR) were higher than normal.
- Patients with CKD are prone to anemia because a decrease in the mean hemoglobin and hematocrit and an increase in RDW-CV were observed.

### ARTICLE INFO

Receive Date: 13 July 2023

Accept Date: 01 October 2023

Available online: 04 December 2023

DOI: 10.22034/TRU.2023.416303.1161

#### \*Corresponding Author:

Esmat Radmanesh

Email: [e.radmanesh@abadanums.ac.ir](mailto:e.radmanesh@abadanums.ac.ir)

Address: Department of Physiology, Abadan University of Medical Sciences, Abadan, Iran

### ABSTRACT

#### Introduction

Chronic Kidney Disease (CKD) is a condition where the kidneys have abnormal structure or function that lasts for more than three months, can have negative health effects, and often does not show symptoms in the beginning. In that research, we tried to examine the diagnostic markers from the laboratory to find clues for a faster diagnosis of this disease.

#### Methods

This paper is a cross-sectional analytical study on 107 patients with CKD hospitalized in Abadan University of Medical Sciences educational hospitals from March 21, 2017, to March 19, 2020. Once the necessary permits were obtained, the laboratory information of patients was received from HIS. The data was analyzed by SPSS version 16 software. Statistical significance is considered when P-value > 0.05.

#### Results

Out of 107 patients with CKD in the study, 55 (51.4%) were female and 52 (48.6%) were male. The mean age of the group was 57.9±17.42 years. The means of renal diagnostic markers such as creatinine 7.42±4.55 and BUN 56.97±36.78 were higher than normal. Also, the mean coagulation markers, including PT (15.86±9.89), PTT (47.65±29.11), and INR (1.54±1.07), were higher than normal. The mean of hematological diagnostic markers, including hemoglobin and hematocrit, was lower than normal. The mean RDW-CV (16.97±4.19) and white blood cells (11.19±9.01) were higher than normal.

#### Conclusions

This study showed that renal markers (creatinine and BUN) and coagulation factors (PT, PTT, and INR) were higher than normal. In this study, it was observed that people with CKD are prone to anemia because a decrease in the mean hemoglobin and hematocrit and an increase in RDW-CV were observed.

**Keywords:** Kidney; Coagulation factors; Hemoglobin; Creatinine

## Introduction

More than 750 million people around the world are affected by kidney disease (1). Although cardiac and cerebrovascular diseases and cancer are the primary causes of mortality related to chronic illnesses, kidney diseases have now become widespread. They are also one of the top causes of death in industrialized nations (2). In high-income countries, non-communicable diseases, such as diabetes and hypertension, are the leading causes of CKD. While in low- and middle-income countries, this disease has additional potential etiologies, including infectious diseases and environmental toxins (3).

Chronic Kidney Disease is a condition where the kidneys have abnormal structure or function for over 3 months, with associated health implications (4). Diabetes mellitus (DM) is the most common cause of CKD (5). CKD is frequently clinically silent in the early stages, resulting in most patients being detected shortly before or with the onset of symptomatic disease when the impact of available therapeutics is markedly reduced (6).

CKD may have asymptomatic metabolic complications like metabolic acidosis, anemia, and mineral and electrolyte disorders (7). Kidney disease is usually asymptomatic in the early stages, so early diagnosis is essential to reduce the risk of subsequent complications (8). Therefore, early diagnosis of this disease is necessary for effective treatment of CKD. In that research, we tried to examine the diagnostic markers from the laboratory to find clues for a faster diagnosis of this disease.

## Methods

This investigation is a cross-sectional analytical study on patients with CKD hospitalized in educational hospitals of Abadan University of Medical Sciences from March 21, 2017, to March 19, 2020. The criteria for inclusion in the article were patients with CKD hospitalized in the educational hospitals of Abadan from March 21, 2017, to March 19, 2020, whose laboratory information was available. Exclusion criteria were people with chronic kidney disease hospitalized in educational hospitals of Abadan, whose laboratory information was unavailable. This study was approved by the Ethics Committee of Abadan University of Medical Sciences, Abadan, Iran (Ethical Approval ID: IR.ABADANUMS.REC.1399.043).

After obtaining the necessary permissions, by referring to the medical records department of Abadan and Khorramshahr hospitals, the laboratory information of 107 hospitalized CKD patients from March 21, 2017, to March 19, 2020, available in HIS was obtained. The selection of samples was done randomly and only based on their diagnosis.

The information included renal factors (Creatinine (Cr), Blood Urea Nitrogen (BUN), serum potassium (K) and serum sodium (Na)); liver factors (SGOT or AST and

SGPT or ALT); hematologic factors White Blood Cell (WBC), Red Blood Cells (RBC), Mean Corpuscular Hemoglobin Concentration (MCHC), Lymphocytes (lymph), Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), Red Cell Distribution Width (RDW-CV) and coagulation factors (PT, PTT, Platelets and INR).

When describing the data, we utilize mean and standard deviation for quantitative variables and frequency and percentage for qualitative variables. We also check the normality of quantitative variables using the Kolmogorov-Smirnov test. We analyzed the data using a T-test and one-way ANOVA with SPSS version 16 software. Statistical significance is considered when  $P\text{-value} > 0.05$ .

## Results

Out of 107 patients with CKD in the study, 55 (51.4%) were female and 52 (48.6%) were male. The group's mean was  $57.9 \pm 17.42$  years, with the youngest and the oldest being 20 and 88 years old, respectively.

In CKD patients, the highest frequency was related to the age group of 60-69 years 31(29%) (Table 1). Among the investigated factors, the mean BS  $172.98 \pm 135.24$  was higher than normal. The means of renal diagnostic markers such as creatinine  $7.42 \pm 4.55$  and BUN  $56.97 \pm 36.78$  were higher than normal. Also, the mean coagulation markers, including PT ( $15.86 \pm 9.89$ ), PTT ( $47.65 \pm 29.11$ ), and INR ( $1.54 \pm 1.07$ ), were higher than normal. The mean of hematological diagnostic markers, including hemoglobin and hematocrit, was lower than normal. The mean RDW-CV ( $16.97 \pm 4.19$ ) and white blood cells ( $11.19 \pm 9.01$ ) were higher than normal. Liver enzymes, including ALT and AST, were in the normal range (Table 2). There was no significant difference in laboratory diagnostic factors in this study between men and women (Table 3) and different age groups (Table 2).

## Discussion

In this study, laboratory diagnostic markers were investigated in patients with CKD. The renal diagnostic markers (creatinine and BUN) were observed to be higher than normal in these patients. Also, by examining the hematological factors, it was observed that the mean hematocrit and hemoglobin are lower than normal in these patients, and the mean white blood cell and RDW-CV are higher than normal.

**Table 1.** Frequency of patients with CKD by age group

Age, year	N (%)
≤ 49	28 (26.2)
50-59	21 (19.6)
60-69	31 (29)
≥70	27 (25.2)

**Table 2.** The mean and standard deviation of the investigated factors in patients with CKD based on age group

Variables	Age group					F**	P-value
	≤49	50-59	60-69	≥70	Total		
BS (mg/dL)	153.93±82.94	227.40±258.52	180.93±95.49	141.73±47.39	172.98±135.24	1.79	0.15
BUN (mg/dL)	54.21±44.43	54.47±28.54	62.57±34.10	55.15±38.62	56.97±36.78	0.33	0.79
Cr (mg/dL)	8.95±5.67	7.92±4.73	7.20±3.76	5.71±3.39	7.42±4.55	2.44	0.06
Na (mEq/L)	137.93±5.17	136.35±4.18	138.06±4.24	139.08±4.75	137.95±4.64	1.31	0.72
PT (s)	17.53±12.24	13.06±2.04	13.71±3.74	19.82±15.39	15.86±9.89	1.99	0.12
PTT (s)	51.37±32.28	44.29±23.28	42.38±20.84	55.20±40.83	47.65±29.11	0.77	0.51
INR	1.70±1.24	1.22±0.40	1.31±0.63	2.00±1.58	1.54±1.07	2.18	0.09
WBC (/mm <sup>3</sup> )	13.28±9.81	9.27±4.65	10.81±11.99	11.01±6.62	11.19±9.01	0.81	0.48
RBC (million/mm <sup>3</sup> )	3.68±1.26	4.20±1.63	4.08±1.11	4.28±1.95	4.05±1.50	0.83	0.47
MCV (μm <sup>3</sup> )	86.61±8.03	83.70±9.23	87.53±9.85	89.92±10.62	87.14±9.59	1.73	0.16
Hb (g/dL)	9.88±3.24	13.20±14.38	10.77±2.46	10.61±2.44	10.99±6.88	0.98	0.40
Hematocrit (%)	31.56±9.83	32.91±7.67	35.05±8.25	34.96±6.84	33.66±8.28	1.11	0.34
MCH (pg/cell)	27.94±3.53	26.71±3.90	28.13±3.85	27.55±4.09	27.65±3.82	0.63	0.59
PLT (mm <sup>3</sup> )	227.46±98.65	22.47±99.60	217.07±113.13	201.92±97.93	217.03±101.96	0.30	0.81
RDWCV (%)	17.80±6.88	16.98±3.61	16.80±2.44	16.32±2.38	16.97±4.19	0.56	0.64
ALT (IU/L)	13.13±10.16	9.60±5.06	13.65±7.76	19.53±21.89	14.47±13.55	1.43	0.24
AST (IU/L)	15.92±10.70	12.00±5.27	22.70±30.43	35.90±45.22	22.48±29.68	2.33	0.08
LYMPH (%)	21.10±12.65	26.10±14.41	25.52±14.38	21.69±15.32	23.52±14.08	0.70	0.55
Neutrophil (%)	78.24±13.52	74.14±15.21	71.67±18.28	77.84±15.33	75.37±15.80	0.89	0.45
K (mEq/L)	5.02±0.96	4.77±0.95	5.13±1.30	4.92±0.99	4.98±1.07	0.96	0.41

\*Standard deviation

\*\* F-value conducted from ANOVA test.

BS: Blood sugar, BUN: blood urea nitrogen, Cr: creatinine, Na: sodium, PT: prothrombin time, PTT: partial thromboplastin time, INR: international normalized ratio, WBC: white blood cell, RBC: red blood cell, MCV: Mean corpuscular volume, Hb: hemoglobin, RDWCV: Red cell distribution width, MCH: mean corpuscular hemoglobin, PLT: platelet, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LYMPH: lymphocyte

**Table 3.** The mean and standard deviation of the investigated factors in patients with CKD based on the gender of the patients

Variables	Sex		T*	P-value
	Male	Female		
BS (mg/dL)	176.45±145.74	169.58±125.42	0.25	0.79
BUN (mg/dL)	53.12±30.17	60.61±42.05	-1.05	0.29
Cr (mg/dL)	7.63±5.09	12.99±43.14	-0.87	0.38
Na (mEq/L)	138.66±3.93	137.3±5.16	1.49	0.13
K (mEq/L)	4.92±1.00	5.04±1.14	-0.99	0.32
Ca (mEq/L)	8.91±0.87	8.75±1.04	0.76	0.44
PT (s)	14.94±8.04	16.66±11.31	-0.75	0.45
PTT (s)	46.34±25.79	48.80±32.03	-0.36	0.71
INR	1.44±0.87	1.63±1.21	-0.77	0.44
WBC (/mm <sup>3</sup> )	12.18±10.91	10.25±6.72	1.09	0.27
RBC (million/mm <sup>3</sup> )	4.20±1.86	3.91±1.06	0.98	0.32
MCV (μm <sup>3</sup> )	86.76±8.51	87.47±10.54	-0.37	0.70
Hb (g/dL)	10.50±2.78	11.44±9.18	-0.70	0.48
Hematocrit (%)	33.82±8.37	33.52±8.27	0.18	0.85
MCH (pg/cell)	28.19±3.58	27.15±4.01	1.40	0.16
PLT (mm <sup>3</sup> )	211.47±89.04	222.18±113.21	-0.53	0.59
RDWCV (%)	16.56±2.95	17.36±5.09	-0.96	0.33

<b>ALT (IU/L)</b>	13.35±11.66	62.19±242.35	-1.22	0.22
<b>AST (IU/L)</b>	19.44±20.30	80.16±279.63	-1.33	0.19
<b>LYMPH (%)</b>	23.51±13.69	23.52±14.62	-0.00	0.99
<b>Neutrophil (%)</b>	76.26±13.47	268.10±1240.26	-0.99	0.32

BS: Blood sugar, BUN: blood urea nitrogen, Cr: creatinine, P: phosphorus, Na: sodium, K: potassium, Ca: Calcium, PT: prothrombin time, PTT: partial thromboplastin time, INR: international normalized ratio, WBC: white blood cell, RBC: red blood cell, MCV: Mean corpuscular volume, Hb: hemoglobin, MCH: mean corpuscular hemoglobin, PLT: platelet, RDWCV: Red cell distribution width, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LYMPH: lymphocyte, K: potassium

\*: T-value conducted from Independent T-test.

According to a study by Suresh M et al., in 2012, patients with chronic kidney disease often have lower blood indices due to a variety of factors including impaired erythropoietin production, increased hemolysis, suppression of bone marrow erythropoiesis, hematuria, blood loss from the digestive system. Hematological parameters are negatively correlated with serum creatinine concentration. The majority of individuals with chronic kidney disease who have abnormal levels of RBC, hemoglobin, and hematocrit have levels lower than normal, while the majority of those with abnormal levels of urea and creatinine have levels higher than normal (9).

Also, according to Afshan Zeeshan Wasti et al., chronic kidney patients have significantly lower mean indices of red blood cells, hemoglobin, MCH, and MCHC (10). Fatih KAMIŞ et al., (2021) reported a significant increase in blood serum creatinine levels in patients with chronic kidney disease. However, no significant differences were found in WBC, neutrophil, lymphocyte, and platelet indices (11). The present paper's results indicated that mean coagulation markers PT, PTT, and INR were higher than normal in CKD patients.

According to a study conducted by Xia and colleagues in 2023, there were no significant statistical differences in PT levels between patients with renal failure and the control group. However, male patients with renal failure stated significant differences in PTT levels in comparison with the control group. The research suggests that PTT levels may serve as an indicator of coagulation abnormalities in male patients with renal failure (12). In the present study, liver enzymes (AST and ALT) were within the normal range in patients with CKD.

Musazadeh et al., (2023) reported that patients with chronic kidney disease had lower ALT and AST serum levels than the control group. However, the two groups had no significant difference (13).

Sette et al., found that serum AST and ALT levels were negatively correlated with serum creatinine levels and positively correlated with GFR. They also observed higher liver enzyme levels in patients with lower stages of CKD (14). According to Dyab Allawi et al., Dialysis patients and CKD cases had significantly lower mean ALT and AST levels (15).

Among the limitations of this study were incomplete patient information in HIS and low sample size. It is suggested that in future studies, more extensive studies with larger sample sizes among different ethnic groups and comparisons with the control group should be conducted.

### Conclusions

This study showed that renal markers (creatinine and BUN) and coagulation factors (PT, PTT, and INR) were higher than normal. In this study, it was observed that people with CKD are prone to anemia because a decrease in the mean hemoglobin and hematocrit and an increase in RDW-CV was observed.

### Authors' contributions

Conceptualization: ER, Formal analysis: AZ, NK, Investigation: ER, AZ, and ABK, Methodology: ER, ABK, HMF, TEF, MMSH, and KhK, Project administration: ER, Validation: HMF, Writing—original draft: ABK, Writing—review & editing: ER.

### Acknowledgments

The authors gratefully acknowledge the Shahid Beheshti Educational Hospital's staff in Abadan city, the Clinical Research Development Unit of Valiasr Educational Hospital, Abadan University of Medical Sciences, and the Clinical Research Development Unit of Taleghani Educational Hospital, Abadan University of Medical Sciences.

### Conflict of interest

All authors declare that there is no conflict of interest.

### Funding

There was no funding.

### Ethics statement

The Ethics Committee of Abadan University of Medical Sciences approved this study (Ethical Approval ID: IR.ABADANUMS.REC.1399.043).

### Data availability

Data will be provided on request.

**Abbreviations**

ALT	Alanine transaminase
AST	Aspartate aminotransferase
BS	Blood sugar
BUN	Blood urea nitrogen
Cr	Creatinine
INR	International normalized ratio
K	Potassium
MCH	Mean corpuscular hemoglobin
MCHC	Mean corpuscular hemoglobin concentration
MCV	Mean corpuscular volume
Na	Sodium
PT	Prothrombin time
PTT	Partial thromboplastin time
RBC	Red blood cell
RDW-CV	Red Cell Distribution Width
WBC	White blood cell

**References**

1. Crews DC, Bello AK, Saadi G. 2019 World Kidney Day Editorial - burden, access, and disparities in kidney disease. *Jornal brasileiro de nefrologia*. 2019;41(1):1-9.
2. Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, et al. The burden of kidney disease: improving global outcomes. *Kidney international*. 2004;66(4):1310-4.
3. Lunyera J, Mohottige D, Von Isenburg M, Jeuland M, Patel UD, Stanifer JW. CKD of Uncertain Etiology: A Systematic Review. *Clinical journal of the American Society of Nephrology : CJASN*. 2016;11(3):379-85.
4. Dehghani A, Alishavandi S, Nourimajalan N, Fallahzadeh H, Rahmanian V. Prevalence of chronic kidney diseases and its determinants among Iranian adults: results of the first phase of Shahedieh cohort study. *BMC Nephrology*. 2022;23(1):203.
5. Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. *Journal of the American Society of Nephrology : JASN*. 2005;16(1):180-8.
6. O'Seaghdha CM, Lyass A, Massaro JM, Meigs JB, Coresh J, D'Agostino RB, Sr., et al. A risk score for chronic kidney disease in the general population. *The American journal of medicine*. 2012;125(3):270-7.
7. Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP, et al. Timing of onset of CKD-related metabolic complications. *Journal of the American Society of Nephrology : JASN*. 2009;20(1):164-71.
8. Gaeini Z, Mirmiran P, Bahadoran Z, Azizi F. Association of Tea, Coffee, Caffeine and Chronic Kidney Disease: Tehran Lipid and Glucose Study. *Iranian Journal of Epidemiology*. 2022;18(3):214-23.
9. Suresh M, Mallikarjuna reddy N, Sharan B Singh M, Hari Krishna Bandi, Shrivya keerthi G, M C. Hematological Changes in Chronic Renal Failure. *Int J Sci Res Publ*. 2012;2(9):1-4. <http://www.ijsrp.org/research-paper-0912.php?rp=P09160>
10. Wasti AZ, Iqbal S, Fatima N, Haider S. Hematological disturbances associated with chronic kidney disease and kidney transplant patients. *Int J Adv Res*. 2013;1:48-54. doi: 10.4103/joah.joah\_13\_19
11. Kamis F, Bakirdogen S, B Ç. The relationship between renal resistive index and simple hematologic indices in patients with chronic kidney disease. *J Health Sci Med*. 2021;4(1):45 - 8.
12. Alshammary AF, Alsowyan M, Alawain A, Alghamdi S, Alsiary R, Alsofyani A, et al. PT and PTT; Are They Significant Indicators of Poor Prognosis in Severe Renal Failure Patients? *Acta Biomed*. 2023;94(2):e2023118. doi: 10.23750/abm.v94i2.15527.
13. Moosazadeh M, Espahbodi F, Afshari M, Eslami A. Can CBC Profile and Liver Function Test Predict Chronic Kidney Disease among a Normal Population? *International journal of preventive medicine*. 2023;14:2.
14. Sette LH, Lopes EP. The reduction of serum aminotransferase levels is proportional to the decline of the glomerular filtration rate in patients with chronic kidney disease. *Clinics (Sao Paulo, Brazil)*. 2015;70(5):346-9.
15. Allawi AAD, Mahmood MY, F aH. Correlation between Liver Enzymes and Chronic Kidney Disease Iraqi Patients With or Without Hemodialysis. *IOSR-JDMS*. 2017;16(10):74-81.

**Author (s) biosketches**

**Balizadeh Karami A**, MD, Student Research Committee, Abadan University of Medical Sciences, Abadan, Iran.

Email: [alibalizadeh1998@gmail.com](mailto:alibalizadeh1998@gmail.com)

**Zahedi A**, MSc, Department of Public Health, Asadabad School of Medical Sciences, Asadabad, Iran.

Email: [atefe.zahedi@gmail.com](mailto:atefe.zahedi@gmail.com)

**Kamyari N**, Assistant professor, Department of Public Health, School of Health, Abadan University of Medical Sciences, Abadan, Iran.

Email: [n.kamyari@yahoo.com](mailto:n.kamyari@yahoo.com)

**Mojiri-Forushani H**, Assistant professor, Department of Pharmacology, School of Medicine Abadan University of Medical Sciences, Abadan, Iran.

Email: [dr.mojiri@yahoo.com](mailto:dr.mojiri@yahoo.com)

**Eghdampanah Foumani T**, MD, Student Research Committee, Abadan University of Medical Sciences, Abadan, Iran.

Email: [tina.eghdam@gmail.com](mailto:tina.eghdam@gmail.com)

**Shadravan MM, MD**, Student Research Committee, Abadan University of Medical Sciences, Abadan, Iran.

Email: [shadravanmehdi1380@gmail.com](mailto:shadravanmehdi1380@gmail.com)

**Kanani KH, MSc**, Clinical Research Development Unit, Taleghani Educational Hospital, Abadan University of Medical Sciences, Abadan, Iran.

Email: [khadije.kanani.2020@gmail.com](mailto:khadije.kanani.2020@gmail.com)

**Radmanesh E**, Associate professor, Department of Physiology, School of Medicine, Abadan University of Medical Sciences, Abadan, Iran.

Email: [e.radmanesh@abadanums.ac.ir](mailto:e.radmanesh@abadanums.ac.ir)

**How to cite this article**

Balizadeh Karami A, Zahedi A, Kamyari N, Mojiri-Forushani H, Eghdampanah Foumani T, Shadravan MM, Kanani KH, Radmanesh E. Evaluation of Liver Enzymes, Hematologic and Coagulation Factors in Patients with Chronic Kidney Disease. 2023 Nov;5(4):161-166.

DOI:10.22034/TRU.2023.416303.1161

URL:[https://www.transresurology.com/article\\_180507.html](https://www.transresurology.com/article_180507.html)

